Allergy Therapeutics PLC Notice of Results (9619N)
August 15 2017 - 2:00AM
UK Regulatory
TIDMAGY
RNS Number : 9619N
Allergy Therapeutics PLC
15 August 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Notice of Preliminary Results
15 August 2017 Allergy Therapeutics (AIM:AGY), the fully
integrated specialty pharmaceutical group specialising in allergy
vaccines, will issue its preliminary results for the year ended 30
June 2017 on Thursday 28 September 2017.
Manuel Llobet, Chief Executive Officer, and Nick Wykeman,
Finance Director, will hold a presentation and conference call for
analysts on the day of results at 9:30am BST at The Dome Room, 1
Cornhill, London, EC3V 3ND.
Please contact Consilium Strategic Communications for further
details.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Philippa Gardner
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical group focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary products and
third party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group employs c.500 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORFMGMRKDKGNZM
(END) Dow Jones Newswires
August 15, 2017 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Sep 2023 to Sep 2024